$CGEM (CULLINAN THERAPEUTICS) — 8-K: Zipalertinib Plus Chemo Cuts Progression Risk 50% in First-Line EGFR Exon 20 NSCLC

In the Phase 3 REZILIENT3 trial, zipalertinib plus platinum-based chemotherapy improved median progression-free survival by 6.0 months versus chemotherapy alone in first-line EGFR exon 20 insertion mutation NSCLC (HR=0.50; 95% CI, 0.34-0.73; P=0.00015). At the interim overall survival analysis with 30% event maturity, the hazard ratio for death was 0.72 (95% CI, 0.42-1.23), with follow-up ongoing. The combination also produced significantly higher response rates than chemotherapy alone. Results were presented in a Presidential Symposium at WCLC 2026.

In the Phase 3 REZILIENT3 trial, zipalertinib plus platinum-based chemotherapy improved median progression-free survival by 6.0 months versus chemotherapy alone in first-line EGFR exon 20 insertion mu